Keynotes

Mr. Sidney Taurel
CEO and Chairman
Eli Lilly and Company

Topic: A Way Forward in Pharma: The tough environment accelerates business transformation

Mr. Taurel will present an overview of the major pressures reshaping the business environment of the pharmaceutical industry, including the global health-care payment squeeze, increasing regulatory demands, and the growing complexity of the science underlying drug development. Worst-case scenarios for health-care policy cannot be ruled out in some markets, but Mr. Taurel will argue that the external pressures actually can serve to reshape the industry in a positive way. Using Eli Lilly and Company's transformation as an example, he will describe a more globally integrated R&D complex, therapeutics more tailored to individual patients, greater emphasis on value, and other desirable outcomes of change.

Bio: Sidney Taurel is chairman and chief executive officer for Eli Lilly and Company. He became chief executive officer in July 1998 and chairman of the board of directors on January 1, 1999.

Born a Spanish citizen in Casablanca, Morocco, Taurel became an American citizen in November 1995. After graduating from École des Hautes Études Commerciales, in Paris, France, in 1969, he received a master of business administration degree from Columbia University in 1971.

Taurel joined the Lilly subsidiary Eli Lilly International Corporation in 1971 as a marketing associate. He became general manager of the company's affiliate in Brazil in 1981 and was appointed to the London-based position of vice president of Lilly European operations in 1983. He was named executive vice president of Eli Lilly and Company and president of its pharmaceutical division in 1993. Three years later, he was promoted to president and chief operating officer.

Taurel is past president and a member of the executive committee of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA). He is also a member of the boards of IBM Corporation; McGraw-Hill Companies, Inc.; and the RCA Tennis Championships. And he is a member of the board of overseers of the Columbia Business School, a trustee at Indianapolis Museum of Art, and a member of The Business Council and The Business Roundtable.

In April 2007, he was appointed to the Advisory Committee for Trade Policy and Negotiations. He is an officer of the French Legion of Honor.

Mr. Nicholas Valeriani
Vice President, Office of Strategy & Growth; Executive Committee
Johnson & Johnson

Topic: The Future of Healthcare: Convergence of Opportunities

The dynamics of a rapidly evolving healthcare market -- aging populations, growing prevalence of chronic disease, issues of access and affordability of care, technological advances, globalization -- at once create challenges and opportunities for companies to define innovation not only in terms of products but as patient-centric solutions that address a continuum of complex healthcare needs. In so doing, we will redefine value creation and recommit the industry as a partner with all stakeholders in managing the growing challenges of health care.

Bio: Nicholas J. Valeriani is Vice President, Office of Strategy and Growth, and a member of the Executive Committee of Johnson & Johnson. He was named to this position in January of 2008. He is responsible for identifying new growth platforms for the Corporation distinct from those pursued by existing businesses. The Johnson & Johnson Development Corporation, the Corporate Office of Science and Technology (COSAT) and Worldwide Operations report to him.

Mr. Valeriani began his career in the Johnson & Johnson Family of Companies in 1978 in the Engineering Division of Ethicon, Inc. He advanced through positions in engineering, operations, sales management and product management. In 1991, Mr. Valeriani joined Ethicon Endo-Surgery, Inc., as Vice President of Professional Education, where he was instrumental in establishing the company as a leader in surgeon education. Later that year, he was promoted to the Ethicon Endo-Surgery, Inc. Management Board.

In 1996, Mr. Valeriani was named General Manager of Indigo Medical, Inc. He became President of Ethicon Endo-Surgery, Inc. in 1997. In January, 2001, he was named Company Group Chairman for Johnson & Johnson with responsibility for Ethicon Endo-Surgery, Inc., and the Johnson & Johnson Medical Products Canadian Medical Device & Diagnostic business. The following year he became Worldwide Franchise Chairman for the DePuy franchise, another Johnson & Johnson business.

Mr. Valeriani was promoted to Corporate Vice President, Human Resources, Johnson & Johnson, and became a member of the Executive Committee in September 2003, with responsibility for worldwide management succession and organization development, compensation and benefits, education and training, recruiting, equal opportunity, affirmative action, human resources policies, and employee and labor relations. Mr. Valeriani also chaired the Corporate Contributions Committee and was a member of the Management Compensation Committee and the Pension Committee. Additionally, in the first quarter of 2004, he assumed responsibility for the company's diagnostics businesses and was named Worldwide Chairman, Diagnostics.

In 2004, Mr. Valeriani was named Worldwide Chairman, Cardiovascular Devices and Diagnostics. In 2006, he assumed responsibility for a newly-created Cardiovascular Devices & Diagnostics Group Operating Committee, which included LifeScan, Inc., Cordis Corporation and Ortho-Clinical Diagnostics, Inc. He was named Worldwide Chairman, Medical Devices & Diagnostics, in February of 2007.

Mr. Valeriani currently serves on the Committee on Efficiency & Entrepreneurship at Rutgers University and is a member of the Boards of Directors of Robert Wood Johnson University Hospital and Action for Healthy Kids®.

Born in Newark, New Jersey, Mr. Valeriani received a B.S. degree in industrial engineering from Rutgers University, College of Engineering, and an M.B.A. from Rutgers University, Graduate School of Management. Mr. Valeriani is married and is the father of two children.

Professor Bob Langer
Professor, Inventor, Entrepreneur
MIT Langer Lab

Topic: Creating and Implementing Breakthrough Medical Technology

Several different case studies in the areas of drug delivery, medical devices and biotherapeutics will be discussed. Each study will be examined in terms of the process and excitement of discovery, initial resistance by the scientific community to the discovery in some cases, the way very broad patents were received, how the technologies were transferred to companies, and the way they have been or are trying to be commercialized.

Bio: Robert S. Langer is one of 13 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT).

Dr. Langer has more than 600 issued or pending patents worldwide, one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the United States.

Dr. Langer's patents have been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology and medical device companies; a number of these companies were launched on the basis of these patent licenses. He has served, at various times, on 15 boards of directors and 30 Scientific Advisory Boards of such companies as Wyeth, Alkermes, Mitsubishi Pharmaceuticals, Warner-Lambert, and Momenta Pharmaceuticals. He served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 -- 2002 and as Chairman from 1999-2002.

Dr. Langer has received over 150 major awards. In 2007, he received the 2006 United States National Medal of Science. In 2002, he received the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers and the world's most prestigious engineering prize, from the National Academy of Engineering. He is also the only engineer to receive the Gairdner Foundation International Award; 68 recipients of this award have subsequently received a Nobel Prize. In 2006, he was inducted into the National Inventors Hall of Fame. In 1998, he received the Lemelson- MIT prize, the world's largest prize for invention for being "one of history's most prolific inventors in medicine." In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.

Forbes Magazine (1999) and Bio World (1990) have named Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Langer as one of the 15 innovators world wide who will reinvent our future. Time Magazine and CNN (2001) named Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America. Parade Magazine (2004) selected Langer as one of 6 "Heroes whose research may save your life."

He received his Bachelor's Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.